March 10, 2011
Biomoda (OTCBB: BMOD) has been accepted as an associate member of the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI) focused on the development of molecular technologies for the screening, early diagnosis and target-based treatment of cancer.
According to John Cousins, President of Biomoda, “The EDRN is at the forefront of biomarker research. Our membership opens the door to extraordinary opportunities for collaborative research with our scientific peers who are working in the areas of minimally invasive diagnostics and targeted therapies for cancer.”
February 22, 2011
Biomoda (OTCBB: BMOD) has completed patient enrollment and sample collection for the pilot study to determine the clinical sensitivity and specificity of its CyPath® diagnostic assay for the early detection of lung cancer. The pilot study consisted of two cohorts: (1) a high-risk group of military veterans who smoked more than 20 “pack years” and (2) a smaller positive control group made up of patients diagnosed with lung cancer who have not started treatment.
According to Maria Zannes, CEO of Biomoda, “We are working closely with Dr. Thomas Bauer, Principal Investigator of the CyPath® study, and Dr. Richard Holcomb of Quintiles to evaluate and report top-line results by the end of first-quarter 2011. We believe initial results will show that our assay can both identify and quantify lung cell characteristics that differ between groups of individuals at high risk for developing cancer and those who already have the disease.
January 18, 2011
Biomoda, Inc. (OTCBB: BMOD) is featured on a series of nationally syndicated business radio talk shows airing on the Business Talk Radio Network, Radio America Network, and Money Matters Radio. To date, there have been four interviews, all of which are available on the Company’s Website here.
According to Maria Zannes, Biomoda’s CEO, “Radio broadcasts provide a great opportunity to talk about our CyPath® diagnostic assay for the detection of early-stage lung cancer and progress in our ongoing pilot clinical trial.”
January 12, 2011
Biomoda, Inc. (OTCBB: BMOD) has added Waterbury Pulmonary Associates Research to enroll participants in the Company’s pilot clinical trial. Based in Waterbury, Connecticut, Waterbury Pulmonary is enrolling participants for the positive control group, which are patients diagnosed with cancer but which have not started treatment.
According to Maria Zannes, Biomoda’s CEO, “The addition of Waterbury Pulmonary as an enrollment site for the positive control group should expedite patient recruitment and the completion of our pilot study.”
January 4, 2011
Biomoda, Inc. (OTCBB: BMOD) has named Maria Zannes as CEO of the Company, effective immediately. John Cousins will continue to serve as the Company’s President and CFO.
According to John Cousins, “Maria’s experience in both government and business over the past 30 years is invaluable in terms of moving our molecular marker technology to commercialization. She was instrumental in garnering support and obtaining state funding from the New Mexico Legislature for Biomoda’s veterans screening program, which became the foundation of our pilot study. Maria’s move into the CEO position expands and strengthens our management team, and our state and federal initiatives, as we push toward FDA approval of our CyPath® diagnostic assay.”
December 1, 2010
Biomoda, Inc. (OTCBB: BMOD) selected RCRI, Inc. as its contract research organization (“CRO”) with respect to its upcoming pivotal clinical trial for CyPath, a diagnostic for the early detection of lung cancer.
According to John Cousins, President of Biomoda, “RCRI’s strategic approach to clinical trial design and management will provide additional expertise to the pivotal trial of our CyPath® diagnostic. Conducting clinical trials is increasingly more complex, and RCRI is the perfect partner to help us move our CyPath® product toward FDA approval.”
November 15, 2010
Biomoda, Inc. (OTCBB: BMOD) has engaged Quintiles Global Central Laboratories to help refine the automated image recognition system for measuring the photon emission rate and cell morphology of CyPath®-stained cells to detect early stage lung cancer. Under the terms of the agreement, Quintiles will review CyPath®-stained slides and pap-stained slides to analyze the cell matrices and help Biomoda further calibrate the “signature” of cancer and other aberrant cells that have been labeled with the CyPath® solution.